- Trials with a EudraCT protocol (36)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
36 result(s) found for: Metabolic Process.
Displaying page 1 of 2.
EudraCT Number: 2010-022308-34 | Sponsor Protocol Number: JW/IB/AG | Start Date*: 2011-04-19 | ||||||||||||||||
Sponsor Name:Central Manchester Foundation Hospitals Trust | ||||||||||||||||||
Full Title: Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity | ||||||||||||||||||
Medical condition: Obesity and Metabolic Syndrome (combination of obesity, hypertension, raised blood glucose and cholesterol abnormalities) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003755-64 | Sponsor Protocol Number: DiAPREV/2014 | Start Date*: 2014-11-13 |
Sponsor Name:Helena Elding Larsson | ||
Full Title: A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multip... | ||
Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001217-42 | Sponsor Protocol Number: CN138-489 | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome | |||||||||||||
Medical condition: Subjects with schizophrenia who developed metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) GR (Prematurely Ended) CZ (Completed) ES (Completed) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000633-39 | Sponsor Protocol Number: FEC-TH | Start Date*: 2012-05-21 |
Sponsor Name:Fundación para la Formación e Investigación Sanitaria | ||
Full Title: Extracorporeal photopheresis in liver transplantation. Clinical trial phase I/II safety and efficacy in patients with progressive withdrawal of immunosuppression. | ||
Medical condition: Liver transplantation more than 2 years of evolution to complications of immunosuppression. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004004-36 | Sponsor Protocol Number: ZP-PDProtec-102 | Start Date*: 2013-01-14 |
Sponsor Name:Med. Univ. Wien, UK für Kinder und Jugendheilkunde | ||
Full Title: Pilot Study to define the Feasibility of ex-vivo LPS stimulated Cytokine release for Testing Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal Dialysis (PD) | ||
Medical condition: Peritoneal dialysis is a process of removing metabolic waste products and excess water from the patient's body, replacing the function of the diseased kidneys. Currently, despite the clear benef... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004433-26 | Sponsor Protocol Number: 3638 | Start Date*: 2016-05-04 | |||||||||||||||||||||
Sponsor Name:North Bristol NHS Trust | |||||||||||||||||||||||
Full Title: Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study | |||||||||||||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003873-13 | Sponsor Protocol Number: ESR-14-10613/D1690L00044 | Start Date*: 2016-02-25 | |||||||||||
Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders | |||||||||||||
Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy. | |||||||||||||
Medical condition: Diabetes mellitus type 2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001809-25 | Sponsor Protocol Number: CN138-170 | Start Date*: 2005-12-23 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia. Revised Protocol 02... | ||
Medical condition: patients with schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) CZ (Completed) SE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004833-25 | Sponsor Protocol Number: UNLOCK | Start Date*: 2017-03-29 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
Full Title: Synchronous effect of anesthetics on fMRI, EEG and clinical responses. Development of a more precise system for monitoring anesthetic effect. | ||
Medical condition: General anaesthesia in healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005441-38 | Sponsor Protocol Number: F1K-MC-EVDP | Start Date*: 2008-03-07 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock | |||||||||||||
Medical condition: Septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) FR (Completed) BE (Completed) IT (Completed) PT (Completed) FI (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010640-34 | Sponsor Protocol Number: THYTOTRA | Start Date*: 2009-08-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION. | |||||||||||||
Medical condition: Adult recipients of first liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002879-14 | Sponsor Protocol Number: BioVacSafe-Boostrix® | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v... | |||||||||||||
Medical condition: vaccin against diphtheria, tetanus and pertussis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003543-35 | Sponsor Protocol Number: BioVacSafe–FluadTM | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad... | |||||||||||||
Medical condition: vaccin against influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002356-39 | Sponsor Protocol Number: D/P2/22/8 | Start Date*: 2022-12-14 | |||||||||||
Sponsor Name:Diamyd Medical AB | |||||||||||||
Full Title: DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype | |||||||||||||
Medical condition: Stage 1 or stage 2 pre-type1 diabetes (seropositive for two or more T1D–associated autoantibodies) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003036-12 | Sponsor Protocol Number: IFX-1-P2.2 | Start Date*: 2016-04-22 | ||||||||||||||||
Sponsor Name:InflaRx GmbH | ||||||||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing co... | ||||||||||||||||||
Medical condition: Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004010-10 | Sponsor Protocol Number: UoL001253 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma | |||||||||||||
Medical condition: Previously untreated, high tumour burden follicular lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000078-65 | Sponsor Protocol Number: Rituximab | Start Date*: 2007-01-17 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | |||||||||||||
Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Ongoing) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002766-73 | Sponsor Protocol Number: PHT/2014/44 | Start Date*: 2015-10-26 | ||||||||||||||||
Sponsor Name:Portsmouth Hospitals NHS Trust | ||||||||||||||||||
Full Title: The effect of oral Vitamin D supplementation on endothelial function, vascular inflammation, oxidative stress and insulin sensitivity in patients with impaired fasting glucose: A randomised, double... | ||||||||||||||||||
Medical condition: Impaired fasting glycaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001721-13 | Sponsor Protocol Number: TAK-013/EC-302 | Start Date*: 2005-01-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Center Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001720-21 | Sponsor Protocol Number: TAK-013/EC301 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.